Upstream Bio Statistics
Total Valuation
Upstream Bio has a market cap or net worth of $152.38 million. The enterprise value is -$54.20 million.
| Market Cap | 152.38M |
| Enterprise Value | -54.20M |
Important Dates
The last earnings date was Tuesday, November 10, 2026, before market open.
| Earnings Date | Nov 10, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Upstream Bio has 54.81 million shares outstanding. The number of shares has increased by 5.20% in one year.
| Current Share Class | 54.81M |
| Shares Outstanding | 54.81M |
| Shares Change (YoY) | +5.20% |
| Shares Change (QoQ) | +0.39% |
| Owned by Insiders (%) | 0.07% |
| Owned by Institutions (%) | 68.53% |
| Float | 42.85M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 53.09 |
| Forward PS | 266.67 |
| PB Ratio | 0.65 |
| P/TBV Ratio | 0.65 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 20.45, with a Debt / Equity ratio of 0.00.
| Current Ratio | 20.45 |
| Quick Ratio | 17.46 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -53.53% and return on invested capital (ROIC) is -35.69%.
| Return on Equity (ROE) | -53.53% |
| Return on Assets (ROA) | -34.43% |
| Return on Invested Capital (ROIC) | -35.69% |
| Return on Capital Employed (ROCE) | -75.00% |
| Weighted Average Cost of Capital (WACC) | 13.03% |
| Revenue Per Employee | $38,267 |
| Profits Per Employee | -$2.19M |
| Employee Count | 75 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -88.28% in the last 52 weeks. The beta is 1.61, so Upstream Bio's price volatility has been higher than the market average.
| Beta (5Y) | 1.61 |
| 52-Week Price Change | -88.28% |
| 50-Day Moving Average | 4.24 |
| 200-Day Moving Average | 7.89 |
| Relative Strength Index (RSI) | 35.25 |
| Average Volume (20 Days) | 1,303,439 |
Short Selling Information
The latest short interest is 3.55 million, so 6.48% of the outstanding shares have been sold short.
| Short Interest | 3.55M |
| Short Previous Month | 4.48M |
| Short % of Shares Out | 6.48% |
| Short % of Float | 8.29% |
| Short Ratio (days to cover) | 2.81 |
Income Statement
In the last 12 months, Upstream Bio had revenue of $2.87 million and -$163.94 million in losses. Loss per share was -$3.01.
| Revenue | 2.87M |
| Gross Profit | 2.87M |
| Operating Income | -175.53M |
| Pretax Income | -163.94M |
| Net Income | -163.94M |
| EBITDA | -175.32M |
| EBIT | -175.53M |
| Loss Per Share | -$3.01 |
Balance Sheet
The company has $207.37 million in cash and $789,000 in debt, with a net cash position of $206.58 million or $3.77 per share.
| Cash & Cash Equivalents | 207.37M |
| Total Debt | 789,000 |
| Net Cash | 206.58M |
| Net Cash Per Share | $3.77 |
| Equity (Book Value) | 233.98M |
| Book Value Per Share | 4.27 |
| Working Capital | 232.67M |
Cash Flow
In the last 12 months, operating cash flow was -$168.33 million and capital expenditures -$54,000, giving a free cash flow of -$168.39 million.
| Operating Cash Flow | -168.33M |
| Capital Expenditures | -54,000 |
| Depreciation & Amortization | 205,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -168.39M |
| FCF Per Share | -$3.07 |
Margins
| Gross Margin | 100.00% |
| Operating Margin | -6,115.99% |
| Pretax Margin | -5,712.33% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Upstream Bio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -5.20% |
| Shareholder Yield | -5.20% |
| Earnings Yield | -108.32% |
| FCF Yield | -110.51% |
Analyst Forecast
The average price target for Upstream Bio is $21.40, which is 669.78% higher than the current price. The consensus rating is "Buy".
| Price Target | $21.40 |
| Price Target Difference | 669.78% |
| Analyst Consensus | Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (3Y) | -48.85% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
| Graham Formula Value | n/a |
| Graham Formula Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Upstream Bio has an Altman Z-Score of 35.28 and a Piotroski F-Score of 1.
| Altman Z-Score | 35.28 |
| Piotroski F-Score | 1 |